Compare GSK plc (GSK) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs PepsiCo, Inc. — how do they compare? GSK plc trades at $50.37 (market cap $102.60B), while PepsiCo, Inc. trades at $138.59 (market cap $188.91B). The key difference: PepsiCo, Inc. is the larger of the two by market cap, and PepsiCo, Inc. pays the higher dividend (4.28%). Which is the better fit depends on your goals.
| GSK | PEP | |
|---|---|---|
Market Cap | $102.60B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $170.44 |
52-Week Low | $38.22 | $134.95 |
Enterprise Value | $123.04B | $231.41B |
Dividend Yield | 3.57% | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
PepsiCo (PEP) trades at $138.41, up 0.52% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025, with a net income margin of 10.78% and a P/E ratio of 18.14. Recent earnings have consistently beaten expectations, and analysts project a consensus price target of $158.79. News highlights include price cuts on snacks to address consumer pushback and the cessation of a festival sponsorship.
The outlook for PEP is cautiously optimistic, supported by strong profitability and dividend payments, but faces risks from competitive pressures and price sensitivity. Upside potential exists if North American performance improves as anticipated in upcoming earnings. Investor sentiment is mixed, with a majority of analysts recommending Hold, reflecting balanced growth prospects against near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
